DDInter1110 DDInter1658
Macimorelin, a novel and orally active ghrelin mimetic that stimulates GH secretion, is used in the diagnosis of adult GH deficiency (AGHD). More specifically, macimorelin is a peptidomimetic growth hormone secretagogue (GHS) that acts as an agonist of GH secretagogue receptor, or ghrelin receptor (GHS-R1a) to dose-dependently increase GH levels. Growth hormone secretagogues (GHS) represent a new class of pharmacological agents which have the potential to be used in numerous clinical applications. They include treatment for growth retardation in children and cachexia associated with chronic disease such as AIDS and cancer. Growth hormone (GH) is classically linked with linear growth during childhood. In deficiency of this hormone, AGHD is commonly associated with increased fat mass (particularly in the abdominal region), decreased lean body mass, osteopenia, dyslipidemia, insulin resistance, and/or glucose intolerance overtime. In
Selpercatinib is a kinase inhibitor with enhanced specificity for RET tyrosine kinase receptors (RTKs) over other RTK classes.[A202055, A202052, L13604] Enhanced RET (Rearranged during transfection) oncogene expression is a hallmark of many cancers. Although multikinase inhibitors, including [cabozantinib], [ponatinib], [sorafenib], [sunitinib], and [vandetanib], have shown efficacy in RET-driven cancers, their lack of specificity is generally associated with substantial toxicity. Selpercatinib (LOXO-292) and pralsetinib (BLU-667) represent the first generation of specific RET RTK inhibitors for the treatment of RET-driven cancers.[A202049, A202055, A202052, L13604] Although selpercatinib is currently still under investigation in clinical trial NCT04211337, it was granted accelerated FDA approval on May 8, 2020, for specific RET-driven cancer indications. It is currently marketed under the brand name RETEVMO™ by Loxo Oncology Inc. Selpercatinib is also approved by the European Commission.
Macimorelin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Metronidazole
Macimorelin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Propylthiouracil
Macimorelin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Mecasermin rinfabate
Macimorelin {u} may lead to a major life threatening interaction when taken with {v} Pentamidine
Macimorelin {u} may lead to a major life threatening interaction when taken with {v} Lithium carbonate
Macimorelin may cause a minor interaction that can limit clinical effects when taken with Metronidazole
Macimorelin may cause a moderate interaction that could exacerbate diseases when taken with Propylthiouracil
Macimorelin may cause a moderate interaction that could exacerbate diseases when taken with Mecasermin rinfabate
Macimorelin may lead to a major life threatening interaction when taken with Pentamidine
Macimorelin may lead to a major life threatening interaction when taken with Lithium carbonate